Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Rotigotin, ATC N04BC09 für die Zeit 01.01.2027 - 31.12.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Description
Section 130a Paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in Annex 2 to the contract for the above-mentioned active substance Rotigotine, ATC N04BC09, DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new medicine discount contracts. A discount contract under the authorisation model for the above-mentioned active substance will come into force for the first time on 01.01.2027 and will end on 31.12.2028 (plus extension option 1x12 months). It will automatically end, regardless of this, with the entry into force of the exclusive contract.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-05 - Pegfilgrastim
Techniker KrankenkasseGermanyPharmaceutical productsDeadline in 529 daysPublished on Nov 17, 2026
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 15 Ranibizumab
Techniker KrankenkasseGermanyPharmaceutical productsDeadline in 224 daysPublished on Nov 17, 2026
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-19 - Adalimumab
Techniker KrankenkasseGermanyPharmaceutical productsDeadline in 43 daysPublished on Nov 17, 2026
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Tacrolimus (ATC: D11AH01).
AOK Niedersachsen. Die Gesundheitskasse.GermanyPharmaceutical productsDeadline in 709 daysPublished on Nov 17, 2026